Patents by Inventor Marc-Andre BEAULIEU

Marc-Andre BEAULIEU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRIAZOLE GLYCOLATE OXIDASE INHIBITORS
    Publication number: 20230143491
    Abstract: The present invention provides triazole carboxylic acids and related compounds, as well as pharmaceutically acceptable salts thereof, which are useful as glycolate oxidase inhibitors. Pharmaceutical compositions and methods for treating primary hyperoxaluria, type I (PH) and kidney stones are also described.
    Type: Application
    Filed: June 17, 2022
    Publication date: May 11, 2023
    Inventors: Hans MAAG, Miguel Xavier FERNANDES, Robert ZAMBONI, Elham AKBARIROMANI, Marc-Andre BEAULIEU, Yves LEBLANC, Pallavi THAKUR
  • Triazole glycolate oxidase inhibitors
    Patent number: 11401246
    Abstract: The present invention provides triazole carboxylic acids and related compounds, as well as pharmaceutically acceptable salts thereof, which are useful as glycolate oxidase inhibitors. Pharmaceutical compositions and methods for treating primary hyperoxaluria, type I (PH) and kidney stones are also described.
    Type: Grant
    Filed: July 5, 2019
    Date of Patent: August 2, 2022
    Assignee: CANTERO THERAPEUTICS, INC.
    Inventors: Hans Maag, Miguel Xavier Fernandes, Robert Zamboni, Elham Akbariromani, Marc-Andre Beaulieu, Yves Leblanc, Pallavi Thakur
  • TRIAZOLE GLYCOLATE OXIDASE INHIBITORS
    Publication number: 20210403439
    Abstract: The present invention provides triazole carboxylic acids and related compounds, as well as pharmaceutically acceptable salts thereof, which are useful as glycolate oxidase inhibitors. Pharmaceutical compositions and methods for treating primary hyperoxaluria, type I (PH) and kidney stones are also described.
    Type: Application
    Filed: July 5, 2019
    Publication date: December 30, 2021
    Inventors: Hans MAAG, Miguel Xavier FERNANDES, Robert ZAMBONI, Elham AKBARIROMANI, Marc-Andre BEAULIEU, Yves LEBLANC, Pallavi THAKUR
  • RAF-degrading conjugate compounds
    Patent number: 10787443
    Abstract: The present disclosure provides, inter alia, RAF-Degrading Conjugate Compounds that are useful in the treatment of cancer and other RAF related diseases. Also provided are, pharmaceutical compositions, methods of treatment, and kits comprising a RAF-Degrading Conjugate Compound.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: September 29, 2020
    Assignee: ZAMBONI CHEM SOLUTIONS INC.
    Inventors: Robert Zamboni, Ryan Henning, Xian Alan Ji, Tyler Smith, Bradley Heller, Thumkunta Jagadeeswar Reddy, Sylvain Rocheleau, Marc Andre Beaulieu
  • SUBSTITUTED IMIDAZOPYRIDINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20200299291
    Abstract: This application relates to substituted imidazopyridines, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted imidazopyridines and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Application
    Filed: October 29, 2019
    Publication date: September 24, 2020
    Inventors: Mehrnaz POURASHRAF, Marc-Andre BEAULIEU, Stephen CLARIDGE, Malken BAYRAKDARIAN, Shawn JOHNSTONE, Jeffrey S. ALBERT, Andrew GRIFFIN
  • Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
    Patent number: 10501459
    Abstract: This application relates to substituted imidazopyridines, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted imidazopyridines of Formula I and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: December 10, 2019
    Assignee: Neomed Institute
    Inventors: Mehrnaz Pourashraf, Marc-Andre Beaulieu, Stephen Claridge, Malken Bayrakdarian, Shawn Johnstone, Jeffrey S. Albert, Andrew Griffin
  • RAF-DEGRADING CONJUGATE COMPOUNDS
    Publication number: 20180346457
    Abstract: The present disclosure provides, inter alia, RAF-Degrading Conjugate Compounds that are useful in the treatment of cancer and other RAF related diseases. Also provided are, pharmaceutical compositions, methods of treatment, and kits comprising a RAF-Degrading Conjugate Compound.
    Type: Application
    Filed: April 27, 2018
    Publication date: December 6, 2018
    Inventors: Robert ZAMBONI, Ryan HENNING, Alan JI, Tyler Smith, Bradley HELLER, Thumkunta Jagadeeswar REDDY, Sylvain ROCHELEAU, Marc Andre BEAULIEU
  • SUBSTITUTED IMIDAZOPYRIDINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20180312504
    Abstract: This application relates to substituted imidazopyridines, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted imidazopyridines and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Application
    Filed: October 20, 2016
    Publication date: November 1, 2018
    Inventors: Mehrnaz POURASHRAF, Marc-Andre BEAULIEU, Stephen CLARIDGE, Malken BAYRAKDARIAN, Shawn JOHNSTONE, Jeffery S. ALBERT, Andrew GRIFFIN